Eric Lawitz

List of Publications by Year
in descending order

69	19,015	50244	95218
papers	citations	46 h-index	68 g-index

69	69	69	9514
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology, 2022, 76, 506-517.	1.8	49
2	Oligonucleotideâ€Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology, 2021, 73, 1581-1593.	3.6	4
3	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. American Journal of Gastroenterology, 2021, 116, 1896-1904.	0.2	8
4	Adherence to panâ€genotypic glecaprevir/pibrentasvir and efficacy in HCVâ€infected patients: A pooled analysis of clinical trials. Liver International, 2020, 40, 778-786.	1.9	22
5	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver International, 2020, 40, 1032-1041.	1.9	44
6	Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. The Lancet Gastroenterology and Hepatology, 2020, 5, 918-926.	3.7	28
7	Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virusâ€infected patients: Longâ€term followâ€up results from the openâ€label, Phase II IMPACT study. Health Science Reports, 2020, 3, e145.	0.6	4
8	Efficacy and safety of a twoâ€drug directâ€acting antiviral agent regimen ruzasvir 180Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis, 2019, 26, 1127-1138.	1.0	10
9	Efficacy and safety of ruzasvir 60Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis, 2019, 26, 675-684.	1.0	6
10	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
11	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney International Reports, 2019, 4, 257-266.	0.4	15
12	Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. Antiviral Therapy, 2018, 23, 325-334.	0.6	24
13	Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. Expert Review of Gastroenterology and Hepatology, 2018, 12, 9-17.	1.4	20
14	Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses, 2018, 10, 462.	1.5	2
15	Sofosbuvirâ€velpatasvirâ€voxilaprevir with or without ribavirin in directâ€acting antiviralâ€“experienced patients with genotype 1 hepatitis C virus. Hepatology, 2017, 65, 1803-1809.	3.6	53
16	Antiviral response and resistance analysis of treatment-naÃ¯ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Research, 2017, 140, 151-157.	1.9	5
17	Safety and Efficacy of Elbasvir/Grazoprevir in Patients WithÂHepatitis C Virus Infection and Compensated Cirrhosis: AnÂIntegrated Analysis. Gastroenterology, 2017, 152, 1372-1382.e2.	0.6	79
18	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology, 2017, 153, 113-122.	0.6	215

#	Article	IF	Citations
19	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Journal of Hepatology, 2017, 66, 703-710.	1.8	81
20	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. New England Journal of Medicine, 2017, 377, 1448-1455.	13.9	348
21	The emergence of NS5B resistance associated substitution S282T after sofosbuvirâ€based treatment. Hepatology Communications, 2017, 1, 538-549.	2.0	35
22	Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. The Lancet Gastroenterology and Hepatology, 2017, 2, 814-823.	3.7	14
23	Shortâ€duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology, 2017, 65, 439-450.	3.6	71
24	Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMISTâ€2). Hepatology, 2016, 64, 360-369.	3.6	166
25	Daclatasvir + asunaprevir + beclabuvir Â± ribavirin for chronic <scp>HCV</scp> genotype 1â€infected treatmentâ€naive patients. Liver International, 2016, 36, 189-197.	1.9	23
26	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients WithÂGenotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology, 2016, 151, 893-901.e1.	0.6	46
27	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir andÂSofosbuvir. Gastroenterology, 2016, 151, 501-512.e1.	0.6	192
28	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. Journal of Infectious Diseases, 2016, 213, 1240-1247.	1.9	86
29	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology, 2016, 150, 1590-1598.	0.6	253
30	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.. Clinical Infectious Diseases, 2016, 62, 32-36.	2.9	92
31	Development of sofosbuvir for the treatment of hepatitis C virus infection. Annals of the New York Academy of Sciences, 2015, 1358, 56-67.	1.8	31
32	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	13.9	740
33	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. New England Journal of Medicine, 2015, 373, 2618-2628.	13.9	692
34	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. Journal of Infection, 2015, 70, 197-205.	1.7	35
35	Allâ€oral 12â€week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLYâ€3 phase III study. Hepatology, 2015, 61, 1127-1135.	3.6	598
36	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir inÂanÂOpen-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology, 2015, 149, 971-980.e1.	0.6	77

#	Article	IF	Citations
37	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. Journal of Hepatology, 2015, 63, 564-572.	1.8	132
38	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology, 2015, 62, 79-86.	3.6	232
39	Ledipasvirâ€sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology, 2015, 61, 1793-1797.	3.6	76
40	Next-Generation Regimens. Clinics in Liver Disease, 2015, 19, 707-716.	1.0	6
41	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet, The, 2015, 385, 1075-1086.	6.3	281
42	Sofosbuvir with peginterferonâ€ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology, 2015, 61, 769-775.	3.6	114
43	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. Gastroenterology, 2015, 148, 355-366.e1.	0.6	49
44	Concordance of sustained virological response 4, 12, and 24 weeks postâ€treatment with sofosbuvirâ€containing regimens for hepatitis C virus. Hepatology, 2015, 61, 41-45.	3.6	173
45	Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C. Antiviral Therapy, 2015, 20, 699-708.	0.6	26
46	Infrequent Development of Resistance in Genotype 1â€“6 Hepatitis C Virusâ€“Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. Clinical Infectious Diseases, 2014, 59, 1666-1674.	2.9	199
47	Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology, 2014, 59, 2161-2169.	3.6	77
48	Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2014, 12, 1349-1359.e13.	2.4	87
49	Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). Journal of Hepatology, 2014, 60, 741-747.	1.8	88
50	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. New England Journal of Medicine, 2014, 370, 1879-1888.	13.9	1,080
51	Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection. New England Journal of Medicine, 2014, 370, 1483-1493.	13.9	1,241
52	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. New England Journal of Medicine, 2014, 370, 222-232.	13.9	262
53	Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet, The, 2014, 383, 515-523.	6.3	522
54	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet, The, 2014, 384, 1756-1765.	6.3	751

#	Article	IF	Citations
55	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New England Journal of Medicine, 2014, 370, 211-221.	13.9	1,065
56	Simeprevir With Peginterferon and Ribavirin Leads to High Rates ofÂSVR in Patients With HCV Genotype 1 Who Relapsed After PreviousÂTherapy: A Phase 3 Trial. Gastroenterology, 2014, 146, 1669-1679.e3.	0.6	239
57	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2013, 59, 18-23.	1.8	84
58	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet, The, 2013, 381, 2100-2107.	6.3	265
59	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. New England Journal of Medicine, 2013, 369, 678-679.	13.9	108
60	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infectious Diseases, The, 2013, 13, 401-408.	4.6	313
61	Real World Experience in the Era of First Generation Protease Inhibitors in the Treatment of Hepatitis C. Current Hepatitis Reports, 2013, 12, 189-194.	0.3	0
62	Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders. Gastroenterology, 2013, 144, S-374-S-375.	0.6	18
63	Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. New England Journal of Medicine, 2013, 368, 45-53.	13.9	271
64	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. New England Journal of Medicine, 2013, 368, 1878-1887.	13.9	1,605
65	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. New England Journal of Medicine, 2013, 368, 1867-1877.	13.9	992
66	Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885. Antimicrobial Agents and Chemotherapy, 2013, 57, 6333-6340.	1.4	89
67	Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine, 2012, 366, 216-224.	13.9	580
68	Telaprevir for Retreatment of HCV Infection. New England Journal of Medicine, 2011, 364, 2417-2428.	13.9	1,466
69	Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New England Journal of Medicine, 2011, 364, 1207-1217.	13.9	1,538